ACVR1 and neoplasm: Inhibition of ALK2, via pharmacologic or genetic means, led to inhibition of proliferation and induction of apoptosis, as well as a selective reduction in cell viability in patient-derived in vitro tumour models, and enhanced survival of mice bearing orthotopic ACVR1-mutant patient-derived DIPG xenografts in vivo.